A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial-Reference-Cited by-同舟云学术

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Published:2014-08-14 Issue:11 Volume:261 Page:2101-2111
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Ziemssen Tjalf,Bajenaru Ovidiu A.,Carrá Adriana,de Klippel Nina,de Sá João C.,Edland Astrid,Frederiksen Jette L.,Heinzlef Olivier,Karageorgiou Klimentini E.,Lander Delgado Rafael H.,Landtblom Anne-Marie,Macías Islas Miguel A.,Tubridy Niall,Gilgun-Sherki Yossi

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/article/10.1007/s00415-014-7446-0/fulltext.html

Reference43 articles.

1. Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9:409–416

2. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297

3. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

4. Ziemssen T (2009) Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 277(Suppl 1):S37–S41

5. Coyle PK (2008) Switching algorithms: from one immunomodulatory agent to another. J Neurol 255(Suppl 1):44–50. doi: 10.1007/s00415-008-1007-3.:44-50

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

2. Safety and Effectiveness of Cinnomer^® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study;Archives of Iranian Medicine;2023-11-01

3. The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review;Frontiers in Neurology;2023-07-12

4. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice;Neurodegenerative Disease Management;2022-12

5. Copolymer-1 as a potential therapy for mild cognitive impairment;BRAIN COGNITION;2022